Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants.
Journal Article (Journal Article)
For patients with chronic renal and liver diseases, simultaneous liver and kidney transplantation (SLKT) is the best therapeutic option. The role of a pretransplant donor-specific antibody (DSA) in SLKT is unclear. We report the results of a retrospective review from 7/08 to 10/09 of SLKT at our institution. Monitoring of DSA was performed using single antigen bead assay. Between 7/08 and 10/09, there were six SLKT who had preformed DSA and positive XM (four class I and II DSA, one class I DSA only, one class II only). One-year patient and renal graft survival was 83%. Death-censored liver allograft survival was 100%. Acute humoral rejection (AHR) of the kidney occurred in 66% (three with both class I and II DSA and one with only class II DSA) of patients. In those with AHR, class I antibodies were rapidly cleared (p < 0.01) while class II antibodies persisted (p = 0.25). All patients who had humoral rejection of their kidney had preformed anticlass II antibodies. Liver allografts may not be fully protective of the renal allograft, especially with pre-existing MHC class II DSA. Long-term and careful follow-up will be critical to determine the impact of DSA on both allografts.
Full Text
Duke Authors
Cited Authors
- Dar, W; Agarwal, A; Watkins, C; Gebel, HM; Bray, RA; Kokko, KE; Pearson, TC; Knechtle, SJ
Published Date
- April 2011
Published In
Volume / Issue
- 11 / 4
Start / End Page
- 841 - 847
PubMed ID
- 21446981
Electronic International Standard Serial Number (EISSN)
- 1600-6143
Digital Object Identifier (DOI)
- 10.1111/j.1600-6143.2011.03467.x
Language
- eng
Conference Location
- United States